Continuous infusion of ceftazidime in the empiric treatment of febrile neutropenic children with cancer
| Autor: | Brigitte Nelken, Marie-Odile Husson, Françoise Mazingue, Jean-Hugues Dalle, Magloire Gnansounou, A Lambilliotte |
|---|---|
| Rok vydání: | 2002 |
| Předmět: |
Neutropenia
Adolescent Fever medicine.drug_class medicine.medical_treatment Antibiotics Ceftazidime Antineoplastic Agents Neoplasms Medicine Humans Child Infusions Intravenous Antibacterial agent Chemotherapy Leukopenia business.industry fungi food and beverages Cancer Infant Hematology medicine.disease Anti-Bacterial Agents Oncology Anesthesia Child Preschool Pediatrics Perinatology and Child Health medicine.symptom business Complication medicine.drug |
| Zdroj: | Journal of pediatric hematology/oncology. 24(9) |
| ISSN: | 1077-4114 |
| Popis: | Infection remains one of the most important complications in cancer therapy. The choice of antibiotics and the method of administration can affect results. Beta-lactam antibiotics can be administered by several short injections per day or by continuous infusion. The latter modality may provide superior pharmacokinetics.The authors studied the pharmacokinetics of ceftazidime in children treated for malignancy and in febrile aplasia after chemotherapy. They received a continuous infusion of ceftazidime (200 mg/kg/day) after a loading dose (65 mg/kg/day) administered with amikacin (25 mg/kg/day) and vancomycin (50 mg/kg/day). RESULTS Twenty-three pharmacokinetic studies were performed. Mean ceftazidime serum levels were 31.1 +/- 11.9, 31.2 +/- 10, 32.4 +/- 11.6, 33 +/- 11.6, and 30.4 +/- 12.1 mg/L at 25, 27, 30, 36, and 43 hours, respectively. Treatment was tolerated well. There were no toxic or infectious deaths.Ceftazidime's time-dependent pharmacokinetics shows the advantage of continuous infusion. This study confirmed the feasibility and safety of this administration schedule in the empiric treatment of febrile neutropenic children with cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|